Confronto
Icatibant vs. LL-37
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
138614-30-9
597562-32-8
Peso molecolare
1304.52 g/mol
4493.33 g/mol
Emivita
nessun dato
nessun dato
Sequenza
nessun dato
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESMeccanismo d'azione
Icatibant
Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.
LL-37
LL-37 is a cationic, amphipathic helical peptide and the only member of the cathelicidin family in humans. It is generated by proteolytic cleavage from the C-terminal portion of the precursor protein hCAP18 (CAP-18). Mechanistically it associates with and can permeabilize microbial membranes; in addition it modulates immune cells, influences cytokine release, exerts chemotactic activity, and can bind extracellular self-DNA. Preclinical models have described both anti-inflammatory and pro-inflammatory effects, depending on concentration and tissue context.
Base di evidenze
Evidenza più alta
RCT sull'uomo
Studio sull'uomo
Studi
1
4
di cui sull'uomo
1
1
Effetti registrati
1
4
Contraddizioni aperte
0
1
Eventi avversi documentati
1
0
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Icatibant and LL-37?
- Icatibant is classified as "Ricerca (altro)", while LL-37 is classified as "Ricerca (altro)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Icatibant or LL-37?
- The highest available evidence level is "RCT sull'uomo" for Icatibant and "Studio sull'uomo" for LL-37. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Icatibant and LL-37 in Germany and the United States?
- Germania: Icatibant — Su prescrizione, LL-37 — Solo ricerca. Stati Uniti: Icatibant — Su prescrizione, LL-37 — Solo ricerca. These are factual summaries with source and review date on the individual pages.